The ESMO Asia 2025 (ESMOAsia25) is taking place from December 5-7, 2025, in Singapore
The congress serves as a vital platform to advance cancer care through the latest scientific discoveries, innovative therapies, and evolving clinical practices. Whether you’re a clinician, researcher, or healthcare provider, this gathering offers a front-row seat to the future of oncology.
Deborah Mukherji, Medical Oncologist at Clemenceau Medical Center, Dubai, shared some insights from the event:
“New data from CAPItello-281 at ESMOAsia25:
In the Chinese subgroup with PTEN-deficient mHSPC, capivasertib + abiraterone showed numerically greater rPFS & OS benefit than the global population (rPFS HR 0.55; OS HR 0.54).”
“Inspired by today’s W4O panel at ESMOAsia25, celebrating resilience, leadership, and holistic excellence in cancer care.
Grateful to see such powerful voices driving equity, compassion, and innovation across oncology.”
“Dr Wang presents new FRUSICA-2 data at ESMOAsia25, highlighting the efficacy and safety of fruquintinib monotherapy in patients with advanced RCC after first-line VEGFR-TKI therapy, ORR 35%.”
The Best Poster in the Prostate Cancer category
“Congratulations to the team behind Poster 492P, awarded Best Poster in the Prostate Cancer category at ESMOAsia25!
Important insights from the CUARTET study in Japan evaluating ctDNA-based genomic alterations in patients with mCSPC treated with apalutamide.”
The Best Poster in the GU category
“Congratulations to Poster 555P, awarded Best Poster in the GU (non-prostate) category at ESMOAsia25!
Important findings on TCR repertoire diversity and its association with survival outcomes in UC and RCC patients receiving ICI therapy.”
Promising early results in high-risk post-RP prostate cancer
“GU Mini-Oral session: Promising early results presented at ESMOAsia25.
In high-risk post-RP prostate cancer, adjuvant apalutamide + ADT delivered complete PSA suppression and 100% 6-month bPFS in 103 patients.
Long-term outcomes will determine clinical impact.”
Subgroup data from AMPLITUDE in Chinese BRCA-positive mCSPC patients
“ESMOAsia25, subgroup data from AMPLITUDE in Chinese BRCA-positive mCSPC pts show trends favouring niraparib + AAP over AAP alone across rPFS, TSP, and TST. Supports the importance of early genomic testing and targeted approaches in BRCA-altered mCSPC.”
Enhanced Prostate Cancer Stratification
“ESMOAsia25 In NCCN Int/High-risk localized Prostate Cancer (n=144), both GC and MMAI biomarkers predicted metastasis-free survival.
Adding them improved NCCN 3-yr AUC from 0.71 → 0.84 (GC) and 0.78 (MMAI).
Genomic + AI tools may refine treatment intensification.”
Excellent commentary by Elena Castro
“Excellent commentary, Elena Castro at ESMOAsia25 putting three prostate cancer abstracts into clinical context—highlighting how genomic tools, AI pathology, and targeted therapies are reshaping risk stratification and treatment intensification across the disease continuum.”
“Interesting phase II data at ESMOAsia25:
Neoadjuvant gemcitabine + disitamab vedotin (GD) in HER2+ MIBC achieved a 63.6% pCR rate (75% with 4 cycles).
Downstaging in 86% of patients, with only G1 toxicities.
Encouraging signal for HER2-targeted neoadjuvant therapy in MIBC.”
Early phase II data in high-risk HER2-expressing UTUC
“At ESMOAsia25: Early phase II data in high-risk HER2-expressing UTUC show promising activity for adjuvant disitamab vedotin (anti-HER2 ADC) + tislelizumab (PD-1 inhibitor). Among 47 pts, no recurrences observed at 7.8-mo median follow-up; safety manageable (mostly G1–2 TRAEs).”
A study from India on mitomycin C and capecitabine
“At ESMOAsia25: A study from India shows hypofractionated RT (55 Gy/20 fx) with mitomycin C and capecitabine is feasible for MIBC pts unfit/unwilling for surgery.
77% CR at 3 months, acceptable toxicity, 1-yr OS 100%.
Encouraging bladder-preserving data with good compliance.”
Fantastic discussion by Ravindran Kanesvaran
“Fantastic discussion by Ravindran Kanesvaran at ESMOAsia25, pulling together the key messages from the GU abstracts and offering thoughtful interpretation on how these findings may influence practice.”
Real-world data from India on metastatic penile cancer
“Real-world data from India show metastatic penile cancer affects predominantly rural, low-income men with a median OS just 6.1 months. Major unmet need in LMICs.”
“Patient-reported data are essential to understanding real gaps in cancer care.
IKCC GPS 2025 shows that SDM remains limited across Asia, and up to 92% of kidney cancer patients face treatment barriers. Listening to patients must guide action.”
Prospective trial of toripalimab + lenvatinib in advanced non–clear cell RCC
“Early data from a prospective trial of toripalimab + lenvatinib in advanced non–clear cell RCC show promising activity: ORR 44%, DCR 84%, median PFS 9.2 months, with manageable toxicity.”
Excellent discussion in the GU Mini Oral session by Senthil Rajappa
“Excellent discussion in the GU Mini Oral session this morning, ESMOAsia25 thoughtfully putting new data into clinical context and highlighting what it means for real-world practice across Asia.
Great insights from Dr Senthil Rajappa.”
You can find more posts from ESMO Asia 2025 on OncoDaily.